The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

In this pair of trials, the LAMA component was tiotropium (Spiriva®), a 24-hour agent that has been available as a dry powder inhalation (HandiHaler®) for COPD for some years. The LABA component ...

New users of LAMA-LABA therapy had a 20% reduction in the rate of first pneumonia hospitalization compared with new users of ICS-LABA (HR, 0.80; 95% CI, 0.75-0.86).

In a cohort study, Feldman and colleagues analyzed 137,833 adults (mean age, 70.2 years; 50.4% women) from Optum’s Clinformatics Data Mart with COPD who were newly prescribed either LAMA-LABA ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Many medications can help relieve your COPD symptoms. ... LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations. https: ...

The other single-inhaler on the market for COPD ... colleagues' study provides assurance to patients and clinicians when choosing a dry-powder inhaler over a metered-dose inhaler of LABA-LAMA ...

This includes two medications: LABA and LAMA bronchodilators. There are several fixed-dose LABA/LAMA combination inhalers available — these are inhalers that contain both medications in one.

Based on GOLD criteria, LAMA, LABA or LAMA+LABA therapy should be used as the initial treatment for the majority of patients with COPD, regardless of exacerbation risk. With the 2023 Report, GOLD no ...

For some people with COPD, this will be the only inhaler they need to use every day to control symptoms. Do not use other long-acting, daily inhalers unless your doctor provider says that you should.

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...